Neurocompute Narrative Velocity Map
NEUROCOMPUTE VISUAL SYSTEM

Open the Narrative
Velocity Map

Explore the Parkinson’s research intelligence diagram before entering the Neurocompute platform.

NC
Neurocompute
AI Parkinson’s Intelligence Terminal
NARRATIVE VELOCITY ENGINE

Neurocompute

AI-driven Parkinson’s research intelligence platform exploring emerging signals, forgotten papers, and therapeutic patterns across the biomedical literature universe.

Indexed Papers
1,516
AI Scored
984
Ranked Papers
998
Coverage
1.3%
RESEARCH INTELLIGENCE BOARD

Ranked Parkinson’s Papers

1516 results
LAST INGEST 2026-05-29 06:45 PM
E
Association between heterozygous GBA1 L444P carrier status and risk of Parkinson's disease: A systematic review and meta-analysis.
PMID 41936135 Published: 2026-04-02 Ingested: 2026-04-28 08:58 PM Molecular genetics and metabolism
AI 70.0
Base 23.4
Rank 22.9
AI Summary

This systematic review and meta-analysis of 51 studies reports that heterozygous GBA1 L444P carriers have a markedly increased risk of Parkinson's disease (pooled OR ~9.2) across ancestral groups.

Why It Matters

By providing robust, mutation-specific evidence that L444P is a high-penetrance PD risk variant, the study strengthens justification for GBA1/GCase- and lysosomal-targeted therapies, informs patient stratification and trial enrichment, and highlights gaps in diverse genetic data.

E
Neuronal vulnerability in Parkinson's disease: insights from murine α-synuclein pathology models.
PMID 42002068 Published: 2026-04-17 Ingested: 2026-04-28 08:58 PM Neuroscience
AI 60.0
Base 23.4
Rank 22.9
AI Summary

This review synthesizes murine α‑synuclein pathology models showing selective degeneration of SNpc dopaminergic neurons (notably ALDH1A1‑ neurons) and implicates mitochondrial and lysosomal dysfunction, calcium dysregulation, presynaptic failure, and neuroinflammation as key mechanistic drivers.

Why It Matters

By integrating transcriptomic/proteomic data across models and highlighting model‑ and stage‑dependent vulnerability, the paper helps prioritize cellular mechanisms and vulnerable cell populations for target selection and guides more translationally aligned, stage‑resolved in vivo studies for…

E
Translational prospectives for deep brain stimulation and low-intensity focused ultrasound neuromodulation: IFCN Handbook chapter.
PMID 42016915 Published: 2026-01-01 Ingested: 2026-04-28 08:58 PM Clinical neurophysiology practice
AI 60.0
Base 23.4
Rank 22.9
AI Summary

This chapter reviews advances in deep brain stimulation (including MRI-based connectomics and closed-loop neurophysiology) and low-intensity focused ultrasound neuromodulation, covering mechanisms, transducer and skull-correction hardware, and early clinical studies toward biomarker-guided…

Why It Matters

Relevant to Parkinson's therapeutics because it outlines actionable technological and translational pathways to refine DBS and develop a non-invasive TUS analogue that could expand treatment options, improve targeting, and enable biomarker-driven clinical trials.

E
Genetic Landscape of Monogenic Parkinson's Disease in the African Population-A Systematic Review.
PMID 41958045 Published: 2026-04-09 Ingested: 2026-04-28 08:58 PM Movement disorders : official journal of the Movement Disorder Society
AI 50.0
Base 23.4
Rank 22.9
AI Summary

Systematic review of 64 studies (6,303 PD patients) finds monogenic PD in Africa is allelicly and locus-heterogeneous but dominated in North Africa by the LRRK2 p.Gly2019Ser founder variant, while over 98% of Sub-Saharan African patients lacked an identified molecular cause.

Why It Matters

This matters for therapeutics because the strong, region-specific enrichment of an actionable target (LRRK2 G2019S) supports population-tailored deployment of LRRK2-directed therapies and the clear gap in genetic discovery in Sub-Saharan cohorts indicates that expanded sequencing could reveal…

E
AI 45.0
Base 23.4
Rank 22.9
AI Summary

This systematic review and meta-analysis finds QSM MRI detects disorder-specific iron accumulation—elevated substantia nigra susceptibility in PD, putaminal in MSA, and red nucleus in PSP—with moderate-to-high diagnostic accuracy but notable technical heterogeneity across studies.

Why It Matters

QSM offers a promising non-invasive biomarker to improve diagnostic differentiation and patient stratification for clinical trials in parkinsonian syndromes, but standardization of acquisition and processing is needed to enable reliable therapeutic use.

E
From Bio-Interface Materials to Neural Integration: The Next-Generation Brain-Machine Interfaces Powered by Hydrogels.
PMID 42021568 Published: 2026-04-22 Ingested: 2026-04-28 08:58 PM Advanced materials (Deerfield Beach, Fla.)
AI 45.0
Base 23.4
Rank 22.9
AI Summary

Comprehensive review of hydrogel-based brain–machine interface materials, design, and integration strategies emphasizing their mechanical, electrical, and biocompatible properties and discussing invasive/noninvasive systems, clinical translation, and applications including Parkinson’s disease.

Why It Matters

Hydrogel-enabled BMIs promise more compliant, long-lasting neural recording and stimulation interfaces that could reduce inflammation and enable reliable chronic sensing and closed-loop neuromodulation important for advancing Parkinson’s diagnostics and therapies.

AI Summary

Protocol for a randomized feasibility study comparing computational, patient-specific STN-DBS programming based on anatomy and structural connectivity to conventional monopolar review programming in Parkinson's disease.

Why It Matters

This work is clinically translational: if safe and practical, connectivity-guided individualized programming could shorten time-to-optimal DBS settings and reduce stimulation side effects, improving therapeutic delivery though it does not target underlying disease mechanisms.

E
Sleep depth and cognitive function in Parkinson's disease: An analysis using the Odd's Ratio Product (ORP).
PMID 41962180 Published: 2026-04-08 Ingested: 2026-04-28 08:58 PM Sleep medicine
AI 42.0
Base 23.4
Rank 22.9
AI Summary

This polysomnography study shows that ORP measures of sleep depth—particularly the overnight change in ORP (ORPdiff)—differ between PD and OSA groups and that smaller ORPdiff (less restorative sleep) is associated with worse cognition and greater non-motor symptoms in Parkinson's disease.

Why It Matters

Suggests ORP-derived sleep-depth metrics could serve as objective biomarkers of cognitive vulnerability and non-motor burden in PD and highlights sleep restoration as a potentially modifiable target for therapeutic strategies, although causal mechanisms and intervention data are lacking.

E
Long-Term Outcomes of Subthalamic Nucleus and Globus Pallidus Interna Deep Brain Stimulation for Young-Onset Parkinson Disease.
PMID 41908734 Published: 2026-06-01 Ingested: 2026-04-28 08:58 PM Neurology. Clinical practice
AI 40.0
Base 23.4
Rank 22.9
AI Summary

Large retrospective cohort (n=405) of young-onset Parkinson disease patients shows both GPi and STN deep brain stimulation improve motor symptoms at 1 and 5 years; STN produced greater medication reduction and modest motor benefit while GPi better reduced dyskinesia and motor fluctuations.

Why It Matters

This study informs clinical decision-making about DBS target selection in young-onset PD with actionable, long-term outcome data, but it offers limited mechanistic or drug-discovery insights relevant to molecular therapeutic development.

E
Widespread hnRNP K Mislocalisation Suggests Differential Neuronal Vulnerability in the Neurodegenerative and Ageing Human Brain.
PMID 41952419 Published: 2026-04-01 Ingested: 2026-04-28 08:58 PM Neuropathology and applied neurobiology
AI 40.0
Base 23.4
Rank 22.9
AI Summary

This immunohistochemical study reports widespread neuronal mislocalisation (nuclear loss and cytoplasmic aggregation) of the RNA-binding protein hnRNP K across multiple brain regions in neurodegenerative diseases and aging, with prominent involvement of basal ganglia and a significant correlation…

Why It Matters

Points to hnRNP K mislocalisation as a potential mechanistic contributor or biomarker linked to motor dysfunction in Parkinson’s and related disorders, highlighting a novel RNA-processing–related target for validation and region-specific therapeutic investigation, though findings are exploratory…

E
Freezing of Gait in Parkinson's Disease: A Scoping Review on the Path Towards Real-Time Therapies.
PMID 41977827 Published: 2026-03-25 Ingested: 2026-04-28 08:58 PM Sensors (Basel, Switzerland)
AI 40.0
Base 23.4
Rank 22.9
AI Summary

Scoping review of 60 studies surveying machine- and deep-learning approaches (notably CNNs and LSTMs) using wearable inertial sensors to detect and predict freezing of gait and discussing integration into real-time closed-loop systems.

Why It Matters

Highlights a translational pathway for digital biomarkers and real‑time detection that can enable adaptive therapies (e.g., closed‑loop DBS, exoskeletons) and better clinical endpoints, but offers limited direct molecular or drug‑discovery insights.

AI Summary

Systematic review of 41 studies evaluating single-point lower-trunk magneto-inertial sensors for gait and TUG assessment in Parkinson's and parkinsonisms found moderate-quality evidence (12% high-quality), good reporting of technical aspects but poor clinical characterization and protocol…

Why It Matters

The paper supports single-point mIMUs as a promising, low-cost digital biomarker for monitoring mobility, stratifying patients, and serving as trial endpoints in PD, but emphasizes that standardization and better clinical reporting are needed before wide adoption for therapeutic development.

E
Gait asymmetry in Parkinson's disease - a systematic review and meta-analysis (AsymmGait-Parkinson study).
PMID 41942682 Published: 2026-04-07 Ingested: 2026-04-28 08:58 PM Scientific reports
AI 38.0
Base 23.4
Rank 22.9
AI Summary

Systematic review and meta-analysis of 42 studies (2,111 pwPD) found greater gait asymmetry in Parkinson's disease—especially in step length, step time, and swing time—with swing time asymmetry most sensitive and partially responsive to dopaminergic medication.

Why It Matters

Highlights swing time asymmetry as a measurable, treatment-responsive clinical biomarker that could improve phenotyping and outcome measures for trials and targeted gait interventions, though it offers limited mechanistic or direct therapeutic targets.

E
Clinician and patient perspectives on meaningful Parkinson's disease impacts for digital assessment.
PMID 41940308 Published: 2026-01-01 Ingested: 2026-04-28 08:58 PM Frontiers in neurology
AI 35.0
Base 23.4
Rank 22.9
AI Summary

This study synthesizes clinician and patient priorities—highlighting tremor, rigidity, bradykinesia, global motor function, hand/mobility difficulties, depression, and fatigue—to inform the design of a smartphone/wearable digital endpoint (PD-FIDI).

Why It Matters

By defining clinically and patient-relevant, remotely measurable outcomes, the paper supports development of validated digital endpoints that can improve trial sensitivity and outcome measurement for Parkinson's therapeutics, though it does not address disease mechanisms or interventions directly.

E
Advances in ocular motor and pupil biomarkers for neurological disorders.
PMID 41924697 Published: 2026-01-01 Ingested: 2026-04-28 08:58 PM Brain communications
AI 35.0
Base 23.4
Rank 22.9
AI Summary

This review synthesizes advances in ocular motor and pupillary biomarkers (oculomics/oculometrics), describing saccadic, pursuit, convergence, and pupillometry abnormalities in Parkinson's disease and proposing eye-tracking and VR-based paradigms for diagnosis and monitoring.

Why It Matters

Ocular biomarkers are noninvasive, scalable tools that could improve early detection, patient stratification, and sensitive outcome measures for Parkinson's trials, though the review offers limited direct therapeutic or mechanistic insights and stresses need for large-scale validation.

E
[Speech signal acoustic analysis in the diagnosis of neurological and mental diseases: a systematic review and meta-analysis].
PMID 41984552 Published: 2026-01-01 Ingested: 2026-04-28 08:58 PM Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
AI 30.0
Base 23.4
Rank 22.9
AI Summary

This systematic review and meta-analysis found that Jitter (variation in fundamental frequency) is significantly increased in patients with Parkinson's disease, Alzheimer's disease, and depression, while Shimmer (amplitude variation) was not consistently different, supporting Jitter as a potential…

Why It Matters

A validated, noninvasive speech-based biomarker like Jitter could facilitate screening, remote monitoring, and patient stratification in Parkinson's clinical studies, but it offers little direct insight into molecular therapeutic targets.

E
What factors influence the length of stay and readmission after deep brain stimulation surgery? a tertiary centre study.
PMID 41986786 Published: 2026-04-15 Ingested: 2026-04-28 08:58 PM Acta neurochirurgica
AI 25.0
Base 23.4
Rank 22.9
AI Summary

Retrospective single-center review of 397 DBS procedures (388 patients) identifying older age and anticoagulant use as predictors of prolonged hospital stay, and infections and skull-mounted implants as leading causes of six-month readmissions.

Why It Matters

Useful for perioperative risk stratification, prehabilitation, and resource planning to reduce complications and costs after DBS, but offers minimal mechanistic or therapeutic-discovery insight for Parkinson's disease drug development.

E
AI 25.0
Base 23.4
Rank 22.9
AI Summary

Systematic review of 89 studies (predominantly in Parkinson's disease) characterizing wearable sensor types, placements (ankle common), and machine-learning algorithms for fall detection and calling for standardized, real-world validation.

Why It Matters

Although it doesn't address molecular or therapeutic mechanisms, the paper is useful for Parkinson's drug development because robust, validated wearable fall-detection tools can supply objective real-world endpoints, safety monitoring, and patient stratification to improve clinical trials and care.

E
The Application of Machine Learning to Predict Clinical Outcomes of Deep Brain Stimulation in Parkinson's Disease: A Systematic Review.
PMID 42021831 Published: 2025-01-01 Ingested: 2026-04-28 08:58 PM Medical journal of the Islamic Republic of Iran
AI 25.0
Base 23.4
Rank 22.9
AI Summary

Systematic review of eight small, mostly single-center studies (n=555) applying non-imaging clinical-data machine learning (mostly SVM and k-NN) to classify symptoms or predict DBS outcomes in Parkinson's, finding exploratory, heterogeneous methods with limited external validation.

Why It Matters

Highlights potential for ML to improve DBS patient stratification and outcome prediction but provides little mechanistic or therapeutic insight for Parkinson's drug discovery and is not yet clinically translatable.

E
Progressive Supranuclear Palsy (PSP): An Orthoptic Assessment.
PMID 41970530 Published: 2026-01-01 Ingested: 2026-04-28 08:58 PM The British and Irish orthoptic journal
AI 23.4
Base 23.4
Rank 22.9
AI Summary

Retrospective audit of 26 atypical parkinsonian patients found orthoptic oculomotor and eye-tracker assessment agreed with final neurology diagnoses in ~80.8% of cases for distinguishing suspected PSP from non-PSP.

Why It Matters

This work aids clinical phenotyping and early patient selection for trials or observational studies but provides little mechanistic or therapeutic insight, so its direct value for Parkinson's drug discovery is limited.

E
Access to movement disorders care and advanced surgical therapies in a tertiary care center.
PMID 41988492 Published: 2026-01-01 Ingested: 2026-04-28 08:58 PM Frontiers in neurology
AI 23.0
Base 23.4
Rank 22.9
AI Summary

Retrospective review of 3,286 PD/ET patients at a tertiary movement disorders center (2012–2022) found 12.1% underwent DBS, with higher odds of surgery among Medi‑Cal recipients and low neighborhood SES and lower odds among younger patients, single individuals, and Asian patients, suggesting…

Why It Matters

Although not mechanistic, the paper is valuable for therapeutic implementation because it identifies access and referral disparities that can influence equitable delivery of advanced PD therapies, clinical trial recruitment, and prioritization of outreach or systems-level interventions.

E
AI 20.0
Base 23.4
Rank 22.9
AI Summary

Qualitative care-pathway study of SMaRT-PD, a home-based remote monitoring and CDSS for Parkinson’s, reporting clinician support for benefits (patient empowerment, earlier identification, clinic efficiency) alongside concerns about reduced face-to-face contact and administrative/clinical…

Why It Matters

While it offers little direct mechanistic or drug-discovery insight, the work is valuable for clinical translation—informing remote monitoring, outcome capture, and resource allocation that can indirectly accelerate therapeutic evaluation and implementation.

E
AI 15.0
Base 23.4
Rank 22.9
AI Summary

Cross-sectional and Mendelian-randomization analyses indicate longer leukocyte telomere length is associated with better cognitive performance and causally linked to lower risk of all-cause dementia, Alzheimer’s and vascular dementia, but show no causal association with Parkinson’s disease.

Why It Matters

The study supports telomere length as an aging-related biomarker and possible target for dementia prevention, but provides limited direct, actionable insight for Parkinson’s therapeutic discovery.

E
AI 12.0
Base 23.4
Rank 22.9
AI Summary

Small qualitative study (n=14, ages 67–92, including some participants with Parkinson disease) found a walking-based mobile exergame increased motivation, goal-setting, feedback, self-monitoring, and routine integration but had limited social feature uptake and varied digital literacy.

Why It Matters

This work is useful for designing interventions to increase physical activity and adherence in people with Parkinson's (symptomatic/supportive care and trial engagement), but it has minimal direct relevance to therapeutic discovery because it provides no mechanistic, biomarker, or disease-modifying…

E
Diagnostic pathways and reported latency of Parkinson's disease among Chinese immigrants in New York city: A retrospective chart review.
PMID 41905338 Published: 2026-03-27 Ingested: 2026-04-28 08:58 PM Parkinsonism & related disorders
AI 12.0
Base 23.4
Rank 22.9
AI Summary

Retrospective chart review found Chinese immigrants with idiopathic Parkinson's in NYC had a mean reported diagnostic latency of ~20 months, with gait/postural-onset cases experiencing longer delays than tremor-dominant cases.

Why It Matters

Although not mechanistic, the study identifies sociocultural and healthcare-access barriers that delay diagnosis and treatment initiation, which can affect clinical outcomes and equitable recruitment into therapeutic trials.

Previous
Page 32 of 61
Next
Neurocompute Parkinson’s Narrative Velocity Infographic
NEUROCOMPUTE VISUAL SYSTEM

Open the Narrative Velocity Map

Explore the full Parkinson’s research intelligence diagram.

Expand Intelligence View →
Full Neurocompute Infographic
Full Neurocompute Infographic